menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing Relapse for Schizophrenia Patients: A Look at LAI Antipsychotics

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment. 

Facebook Comments

Schedule14 Aug 2022
Webpack App